Results 131 to 140 of about 989,774 (270)

YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma

Molecular Oncology, EarlyView.
The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy, Samuel Hartzler, Paula A. Vargas Carranza, Shyaman Jayasundara, Madison E. Yates, Nimod D. Janson, Bozhi Liu, Annaleigh Benton, Majid Kazemian, Jason A. Hanna   +9 more
wiley   +1 more source

Factor X deficiency and pregnancy: preconception counselling and therapeutic options [PDF]

, 2011
Danielle Nance, Neil C. Josephson, Kristin Paulyson-Nuñez, Allison James   +3 more
openalex   +1 more source

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

Molecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern, Kristian Holm, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Corinna Bang, Bjørn Naume, Johannes R. Hov, Jon Amund Kyte   +7 more
wiley   +1 more source

A review of the pharmacokinetics, efficacy and safety of high-purity factor X for the prophylactic treatment of hereditary factor X deficiency. [PDF]

Haemophilia, 2022
Payne J, Batsuli G, Leavitt AD, Mathias M, McGuinn CE.   +4 more
europepmc   +1 more source

A bioinformatics screen identifies TCF19 as an aggressiveness‐sustaining gene in prostate cancer

Molecular Oncology, EarlyView.
Gene expression meta‐analysis in multiple prostate cancer patient cohorts identifies Transcription factor 19 (TCF19) as an aggressiveness‐sustaining gene with prognostic potential. TCF19 is a gene repressed by androgen signaling that sustains core cancer‐related processes such as vascular permeability or tumor growth and metastasis.
Amaia Ercilla, Jana R. Crespo, Saioa Garcia‐Longarte, Marta Fidalgo, Sara del Palacio, Natalia Martin‐Martin, Onintza Carlevaris, Ianire Astobiza, Sonia Fernández‐Ruiz, Marc Guiu, Laura Bárcena, Isabel Mendizabal, Ana M. Aransay, Mariona Graupera, Roger R. Gomis, Arkaitz Carracedo   +15 more
wiley   +1 more source

Occurrence and management of severe bleeding episodes in patients with hereditary factor X deficiency. [PDF]

Haemophilia, 2021
Tarantino MD.
europepmc   +1 more source

Modeling hepatic fibrosis in TP53 knockout iPSC‐derived human liver organoids

Molecular Oncology, EarlyView.
This study developed iPSC‐derived human liver organoids with TP53 gene knockout to model human liver fibrosis. These organoids showed elevated myofibroblast activation, early disease markers, and advanced fibrotic hallmarks. The use of profibrotic differentiation medium further amplified the fibrotic signature seen in the organoids.
Mustafa Karabicici, Soheil Akbari, Ceyda Caliskan, Canan Celiker, Ozden Oz, Leman Binokay, Gökhan Karakulah, Serif Senturk, Esra Erdal   +8 more
wiley   +1 more source

A Case Report of Acquired Factor X Deficiency in a Patient With Multiple Myeloma. [PDF]

Cureus, 2021
Sabobeh T, Brugioni EK, Masoud A, Madhusudhana S, Mateescu V.   +4 more
europepmc   +1 more source

Acquired Factor X Deficiency [PDF]

, 2020
National Cancer Institute
openalex   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source